Protein Kinase Inhibitors: all 15,766 studies that test it

Page 157 of 158. Open to participants first (2,605), then studies with results posted, then the rest; newest registration first within each.

• Erlotinib and Cisplatin in Treating Patients With Recurrent or Metastatic Head and Neck CancerCompletedNCT00030576Phase 1/2
• Erlotinib in Treating Patients With Locally Advanced or Metastatic Breast CancerCompletedNCT00030537Phase 2
• ZD 1839 in Treating Patients With Locally Advanced or Metastatic Colorectal CancerCompletedNCT00030524Phase 2
• Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney DysfunctionCompletedNCT00030498Phase 1
• Erlotinib in Treating Patients With Locally Advanced and/or Metastatic Endometrial CancerCompletedNCT00030485Phase 2
• Erlotinib and Carboplatin in Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal CancerCompletedNCT00030446Phase 2
• Imatinib Mesylate in Treating Patients With Chronic Myelogenous LeukemiaCompletedNCT00030394Phase 2
• Open Study of CEP-701 in Patients With Refractory Acute Myeloid Leukemia With FLT-3 MutationCompletedNCT00030186Phase 2
• Gefitinib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung CancerCompletedNCT00029003Phase 2
• Imatinib Mesylate and Cytarabine in Treating Patients With Newly Diagnosed Chronic Myeloid LeukemiaStatus unknownNCT00028847Phase 1/2
• CCI-779 in Treating Patients With Extensive-Stage Small Cell Lung CancerCompletedNCT00028028Phase 2
• Gefitinib in Treating Patients With Persistent or Recurrent Endometrial CancerCompletedNCT00027690Phase 2
• Gefitinib Plus Temozolomide in Treating Patients With Malignant Primary GliomaCompletedNCT00027625Phase 1
• Imatinib Mesylate in Treating Patients With Metastatic MelanomaCompletedNCT00027586Phase 2
• Curcumin for the Prevention of Colon CancerCompletedNCT00027495Phase 1
• Examination of Tamoxifen in Acute Mania in Patients With Bipolar I DisorderCompletedNCT00026585Phase 2
• SU5416 Plus Hormone Therapy and Radiation Therapy in Treating Patients With Prostate CancerCompletedNCT00026377Phase 1
• Gemcitabine With/Out Erlotinib in Unresectable Locally Advanced/Metastatic Pancreatic CancerCompletedNCT00026338Phase 3
• Oxaliplatin With or Without Gefitinib in Treating Patients With Metastatic or Locally Recurrent Colorectal CancerCompletedNCT00026299Phase 1/2
• SU5416 in Treating Patients With Persistent or Recurrent Cervical CancerCompletedNCT00026260Phase 2
• Imatinib Mesylate in Treating Patients With Advanced Cancer and Kidney FailureCompletedNCT00026169Phase 1
• Gefitinib in Treating Patients With Recurrent or Progressive CNS TumorsCompletedNCT00025675Phase 2
• Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver DysfunctionCompletedNCT00025415Phase 1
• Gefitinib in Treating Patients With Recurrent Metastatic Colorectal CancerCompletedNCT00025350Phase 2
• Imatinib Mesylate in Treating Patients With Gastrointestinal Stromal Tumor That Has Been Completely Removed During SurgeryCompletedNCT00025246Phase 2
• Gefitinib in Treating Patients With Malignant MesotheliomaCompletedNCT00025207Phase 2
• Gefitinib and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors or Colorectal CancerCompletedNCT00025142Phase 2
• ZD 1839 in Treating Patients With Prostate Cancer That Has Not Responded to Hormone TherapyCompletedNCT00025116Phase 2
• Radiation Therapy and Tamoxifen in Treating Children With Newly Diagnosed Brain Stem GliomaStatus unknownNCT00024336Phase 2
• SU6668 in Treating Patients With Advanced Solid TumorsCompletedNCT00024206Phase 1
• Trastuzumab and Gefitinib in Treating Patients With Metastatic Breast CancerCompletedNCT00024154Phase 2
• Gefitinib in Treating Patients With Recurrent and/or Metastatic Head and Neck CancerCompletedNCT00024089Phase 2
• SU006668 in Treating Patients With Advanced Solid TumorsStatus unknownNCT00024063Phase 1
• Flavopiridol in Treating Patients With Recurrent or Persistent Endometrial CancerCompletedNCT00023894Phase 2
• Radiation Therapy With or Without SU5416 in Treating Patients With Soft Tissue SarcomaCompletedNCT00023725Phase 1/2
• Gefitinib in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer or Primary Peritoneal CancerCompletedNCT00023699Phase 2
• Steroid Withdrawal in Pediatric Kidney Transplant RecipientsTerminatedNCT00023244Phase 2
• Pediatric Kidney Transplant Without Calcineurin InhibitorsCompletedNCT00023231Not applicable
• Combination Chemotherapy With or Without Peripheral Stem Cell Transplant in Treating Children With Acute Lymphoblastic LeukemiaCompletedNCT00022737Phase 3
• CCI-779 in Treating Patients With Malignant GliomaCompletedNCT00022724Phase 1/2
• Bryostatin 1 Plus Vincristine in Treating Patients With Recurrent or Refractory HIV-Related LymphomaCompletedNCT00022555Phase 1
• CCI-779 in Treating Patients With Metastatic MelanomaCompletedNCT00022464Phase 2
• Phase II/III Study of Anti-VEGF in Neovascular AMDCompletedNCT00021736Phase 2/3
• Combination Chemotherapy in Treating Patients With Advanced CancerCompletedNCT00021073Phase 1
• Combination Chemotherapy and Radiation Therapy With or Without Gefitinib in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By SurgeryCompletedNCT00020709Phase 3
• Perifosine in Treating Patients With Refractory Solid Tumors or Hematologic CancerCompletedNCT00019656Phase 1
• Flavopiridol in Treating Patients With Refractory CancerCompletedNCT00019344Phase 1
• Bryostatin 1 and Cytarabine in Treating Patients With Relapsed Acute Myelogenous LeukemiaCompletedNCT00017342Phase 2
• ZD 1839 in Treating Patients With Glioblastoma Multiforme in First RelapseCompletedNCT00016991Phase 2
• Flavopiridol in Treating Patients With Unresectable or Metastatic Kidney CancerCompletedNCT00016939Phase 2
• Combination Chemotherapy Compared With Hormone Therapy in Treating Patients With Recurrent, Stage III, or Stage IV Endometrial CancerTerminatedNCT00016341Phase 3
• CCI-779 in Treating Patients With Recurrent Glioblastoma MultiformeCompletedNCT00016328Phase 2
• ZD 1839 in Treating Patients With Metastatic or Recurrent Cancer of the Head and NeckCompletedNCT00015964Phase 2
• E7070 in Treating Patients With Stage IV MelanomaCompletedNCT00014625Phase 2
• ZD 1839 in Treating Patients With Stage IV or Recurrent Kidney CancerCompletedNCT00014183Phase 2
• Gefitinib in Treating Patients With Newly Diagnosed Glioblastoma MultiformeCompletedNCT00014170Phase 2
• S0031, ZD 1839 in Treating Patients With Advanced Cancer of the Urinary TractCompletedNCT00014144Phase 2
• Chemotherapy Plus Sargramostim in Treating Patients With Refractory Myeloid CancerCompletedNCT00012376Phase 1
• ZD 1839 in Treating Patients With Metastatic Kidney CancerCompletedNCT00012337Phase 2
• 7-hydroxystaurosporine and Cisplatin in Treating Patients With Advanced Malignant Solid TumorsTerminatedNCT00012194Phase 1
• Flavopiridol in Treating Children With Relapsed or Refractory Solid Tumors or LymphomasCompletedNCT00012181Phase 1
• CCI-779 in Treating Patients With Prostate CancerCompletedNCT00012142Phase 2
• Epirubicin and Tamoxifen With or Without Docetaxel in Treating Postmenopausal Women With Breast CancerStatus unknownNCT00010140Phase 3
• Imatinib Mesylate in Treating Patients With Recurrent Malignant Glioma or MeningiomaCompletedNCT00010049Phase 1/2
• SU5416 in Treating Patients With Metastatic Kidney Cancer That Has Not Responded to Previous TreatmentTerminatedNCT00009919Phase 2
• Comparison of Two Different Doses of STI571 in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal TumorTerminatedNCT00009906Phase 3
• Bryostatin 1 and Cisplatin in Treating Patients With Advanced Recurrent or Residual Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal CancerCompletedNCT00006942Phase 2
• STI571 in Treating Patients With Chronic Myelogenous Leukemia in Blast CrisisCompletedNCT00006475Phase 2
• Radiation Therapy and Tamoxifen in Treating Adults With Newly Diagnosed Supratentorial Glioblastoma MultiformeCompletedNCT00006388Phase 2
• SU5416 in Treating Patients With Advanced or Recurrent Cancer of the Head and NeckCompletedNCT00006361Phase 2
• STI571 in Treating Patients With Recurrent or Refractory Soft Tissue SarcomaCompletedNCT00006357Phase 1/2
• SU5416 in Treating Children With Recurrent or Progressive Brain TumorsTerminatedNCT00006247Phase 1
• SU5416 and Carboplatin to Treat Ovarian CancerCompletedNCT00006155Phase 1
• Combination Chemotherapy in Treating Patients With Unresectable Locally Advanced or Metastatic Stomach CancerCompletedNCT00006081Phase 2
• STI571 in Treating Patients With Chronic Myelogenous Leukemia That Has Not Responded to Interferon AlfaCompletedNCT00006053Phase 2
• STI571 in Treating Patients With Accelerated Phase Chronic Myelogenous LeukemiaCompletedNCT00006052Phase 2
• Comparison of Four Different Treatment Regimens in Treating Women With Stage I Breast CancerStatus unknownNCT00006030Phase 3
• Interleukin-2 Plus Bryostatin 1 in Treating Patients With Melanoma or Kidney CancerCompletedNCT00006022Phase 1
• SU5416 in Treating Patients With Malignant MesotheliomaCompletedNCT00006014Phase 2
• SU5416 in Treating Patients With Refractory or Relapsed Multiple MyelomaCompletedNCT00006013Phase 2
• SU5416 in Treating Patients With Metastatic Melanoma That Has Been Previously TreatedTerminatedNCT00006003Phase 2
• SU5416 in Treating Patients With Metastatic or Locally Recurrent Colorectal CancerTerminatedNCT00006001Phase 2
• Flavopiridol in Treating Patients With Recurrent, Locally Advanced, or Metastatic Soft Tissue SarcomaCompletedNCT00005974Phase 2
• Flavopiridol in Treating Patients With Metastatic Malignant MelanomaCompletedNCT00005971Phase 2
• Bryostatin-1 Plus Cisplatin in Treating Patients With Recurrent or Advanced Cancer of the CervixCompletedNCT00005965Phase 2
• Liposomal Daunorubicin and SU5416 in Treating Patients With Hematologic Cancer That Has Not Responded to Initial TherapyCompletedNCT00005942Phase 1/2
• SU5416 in Patients With AIDS-Related Kaposi's Sarcoma Who Have Not Responded to TreatmentCompletedNCT00005931Phase 2
• Tamoxifen Compared With LY353381 in Treating Women With Newly Diagnosed Breast CancerCompletedNCT00005886Phase 1
• SU5416 in Treating Patients With Advanced, Metastatic, or Recurrent Soft Tissue SarcomasCompletedNCT00005862Phase 2
• Bryostatin 1 Plus Paclitaxel in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-small Cell Lung CancerCompletedNCT00005849Phase 2
• Genistein in Treating Patients With Stage II, Stage III, or Stage IV Prostate CancerWithdrawnNCT00005827Phase 1
• SU5416 and Doxorubicin in Treating Patients With Stage IIIB or Stage IV Inflammatory Breast CancerCompletedNCT00005822Phase 1
• SU5416 and Irinotecan in Treating Patients With Advanced Colorectal CancerCompletedNCT00005818Phase 1/2
• Perifosine in Treating Patients With Advanced Solid TumorsCompletedNCT00005794Phase 1
• SU5416 and Paclitaxel in Treating Patients With Recurrent, Locally Advanced or Metastatic Cancer of the Head and NeckCompletedNCT00005647Phase 1
• SU5416 in Treating Patients With Advanced Solid TumorsCompletedNCT00005642Phase 1
• Bryostatin 1 Plus Paclitaxel in Treating Patients With Locally Advanced or Metastatic Esophageal Cancer or Stomach CancerCompletedNCT00005599Phase 2
• Bryostatin + Fludarabine in Treating Patients With Chronic Lymphocytic Leukemia or Relapsed Indolent Non-Hodgkin's LymphomaCompletedNCT00005580Phase 1
• A Study to Compare Treatment With Sirolimus Versus Standard Treatment in Patients Who Have Received a Kidney TransplantTerminatedNCT00005113Phase 3
• Flavopiridol in Treating Patients With Previously Untreated or Relapsed Mantle Cell LymphomaCompletedNCT00005074Phase 2

← Protein Kinase Inhibitors overview